IDEntifying pAtients with suspicion of infection in the ED who have Low disease severity using midregional proadrenomedullin (MR-proADM) - A pragmatic pivotal randomised controlled trial
In brief
MR-proADM guidance did not reduce hospital admissions in 460 patients
Across nine European emergency departments, hospital admission rates were nearly identical with MR-proADM guidance and standard care: 34.8% versus 33.9%. Fewer patients were admitted in a per-protocol analysis, but the difference was not statistically significant; five-day return visits met the trial's noninferiority threshold in that analysis. The biomarker did not show a clear admission-reducing benefit in this trial.
- Journal
- Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (Q1)
- Published
- 16 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Kordo Saeed, Marta Candella De Abreu, Ana Alonso Morilla, Carlota Clemente-Callejo, Tristan W Clark, Robert Crouch, et al.
- PMID
- 43039140
- DOI
- 10.1016/j.cmi.2026.11.008
Why clinicians should know about it
- Picked for Emergency Medicine (top studies of the week, 22 November 2026): Randomized ED infection pathway trial evaluating admission and safe discharge
- Picked for Biochemistry (medical) (top studies of the week, 22 November 2026): Randomized evaluation of MR-proADM-guided clinical decisions
Abstract
OBJECTIVES: Concentrations of blood biomarker midregional-proadrenomedullin (MR-proADM) can reflect the early microvascular changes and organ dysfunction, which drive the pathophysiology of sepsis. Observational studies and a single-country randomised trial suggested MR-proADM could assist emergency department (ED) clinicians with regards to safer discharges or admission avoidance. The objective of this trial is to evaluate the efficacy/safety of incorporating MR-proADM, into clinical decision-making for hospitalisation or discharge in patients presenting with clinical suspicion of infection to EDs in different countries. METHODS: An open-label randomised-controlled, interventional trial, conducted across nine European EDs. Patients with suspicion of infection and unclear decision of hospitlisataion in the EDs were randomised 1:1 to either MR-proADM-guided algorithm for admission or discharge from ED or to the standard care (SC) arms. The primary efficacy endpoint was the proportion of patients admitted to hospital targeting a reduction in hospitalisation by the intervention compared to SC. The primary safety objective was to show non-inferiority (against 14% margin) in 5-day all-cause ED re-presentation. RESULTS: In low severity illness setting, among 460 patients enrolled a similar hospitalisation rate was seen between the MR-proADM (80/230=34.8%) and the SC (78/230=33.9%) arms in the intention to treat (ITT) population, i.e. a rate difference of 0.9% with 95% CI from -7.8% to 9.5% (p=0.922). In the per-protocol (PP) population, there were fewer admissions (43/168=25.6% when MR-proADM guided vs. 77/221=34.8% in SC), but statistically not significant. Re-presentation within 5-days demonstrated non-inferiority for the MR-proADM-guided arm versus the SC in the PP population with a rate reduction estimated at -2.5% (95% CI [-9.5%, 4.6%], p=0.607). CONCLUSIONS: In this study, the addition of MR-proADM was not associated with statistically different hospitalisation rate. [trial registration: ClinicalTrials.gov (NCT05108883)] Date: November 3rd, 2021.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.